3 Dazzling Dividend Stocks for Your Portfolio Now
Generado por agente de IAEli Grant
domingo, 1 de diciembre de 2024, 5:59 am ET1 min de lectura
ABBV--
Are you looking for dividend stocks that offer a combination of high yields, steady growth, and attractive valuations? Look no further. We've compiled a list of three fantastic dividend stocks that you should consider buying sooner rather than later.
Dividend Stocks
1. AbbVie (ABBV) - A Dividend King with a Bright Future
AbbVie is a pharmaceutical company that has increased its dividend for 52 consecutive years, qualifying it as a Dividend King. With a forward dividend yield of nearly 4.5%, AbbVie offers an appealing income stream. The company's future growth is driven by its upcoming drugs Rinvoq and Skyrizi, which are expected to exceed Humira's peak annual sales by 2027. Despite AbbVie's dismal stock performance this year, its forward earnings multiple of only 12.5x suggests that it may be undervalued.
2. Eli Lilly (LLY) - A Biopharmaceutical Giant with Growing Potential
Eli Lilly has gained attention this year due to its work in the diabetes and weight loss markets. The company's obesity drugs are expected to see significant growth through the end of the decade, providing a substantial tailwind for the company. Eli Lilly's entire lineup and pipeline are impressive, and its dividend track record is equally compelling. With a forward dividend yield of 0.76% and an impressive 75% increase in dividends over the past five years, Eli Lilly is an excellent choice for income seekers.
3. Gilead Sciences (GILD) - A High-Yield Dividend Stock with Strong Fundamentals
Gilead Sciences offers a dividend yield of 4%, more than double the S&P 500 average of 1.6%. The company has been increasing its dividend regularly over the years, with a 32% increase in its dividend over the past five years. Gilead's solid HIV business and fast-growing oncology segment, driven by Trodelvy, are expected to continue driving growth. The company's modest payout ratio of 64% also implies room for future dividend hikes. At a forward price-to-earnings multiple of less than 11, Gilead is a relatively cheap buy.
In conclusion, AbbVie, Eli Lilly, and Gilead Sciences offer attractive dividend yields, strong growth prospects, and favorable valuations. By investing in these three fantastic dividend stocks now, you can take advantage of their current income streams and potential for long-term growth. Keep an eye on these companies as they continue to deliver impressive results and reward shareholders with rising dividends.
LLY--
Are you looking for dividend stocks that offer a combination of high yields, steady growth, and attractive valuations? Look no further. We've compiled a list of three fantastic dividend stocks that you should consider buying sooner rather than later.
1. AbbVie (ABBV) - A Dividend King with a Bright Future
AbbVie is a pharmaceutical company that has increased its dividend for 52 consecutive years, qualifying it as a Dividend King. With a forward dividend yield of nearly 4.5%, AbbVie offers an appealing income stream. The company's future growth is driven by its upcoming drugs Rinvoq and Skyrizi, which are expected to exceed Humira's peak annual sales by 2027. Despite AbbVie's dismal stock performance this year, its forward earnings multiple of only 12.5x suggests that it may be undervalued.
2. Eli Lilly (LLY) - A Biopharmaceutical Giant with Growing Potential
Eli Lilly has gained attention this year due to its work in the diabetes and weight loss markets. The company's obesity drugs are expected to see significant growth through the end of the decade, providing a substantial tailwind for the company. Eli Lilly's entire lineup and pipeline are impressive, and its dividend track record is equally compelling. With a forward dividend yield of 0.76% and an impressive 75% increase in dividends over the past five years, Eli Lilly is an excellent choice for income seekers.
3. Gilead Sciences (GILD) - A High-Yield Dividend Stock with Strong Fundamentals
Gilead Sciences offers a dividend yield of 4%, more than double the S&P 500 average of 1.6%. The company has been increasing its dividend regularly over the years, with a 32% increase in its dividend over the past five years. Gilead's solid HIV business and fast-growing oncology segment, driven by Trodelvy, are expected to continue driving growth. The company's modest payout ratio of 64% also implies room for future dividend hikes. At a forward price-to-earnings multiple of less than 11, Gilead is a relatively cheap buy.
In conclusion, AbbVie, Eli Lilly, and Gilead Sciences offer attractive dividend yields, strong growth prospects, and favorable valuations. By investing in these three fantastic dividend stocks now, you can take advantage of their current income streams and potential for long-term growth. Keep an eye on these companies as they continue to deliver impressive results and reward shareholders with rising dividends.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios